Clinical Scenario

This protocol addresses cytomegalovirus esophagitis that is not mild disease — a severity level at which first-line antiviral treatment has been attempted but has not produced the expected response, requiring escalation to an alternative regimen.

First-Line Failure Condition

The standard initial approach — intravenous ganciclovir, with the option to transition to oral valganciclovir once the patient can absorb and tolerate oral therapy — failed to achieve resolution of the signs and symptoms of CMV esophagitis within 21–42 days. This failure is the trigger for the regimen described here.

Next-Line Treatment Approach

For patients who do not respond to, or cannot tolerate, ganciclovir-based therapy, alternative intravenous antiviral agents — including foscarnet — are used. The complete selection criteria, agents involved, and adjunctive measures are detailed in the full protocol.

Goal: resolution of CMV esophagitis signs and symptoms within 21–42 days

References

IV ganciclovir is the therapy of choice (AI) and can be switched to oral valganciclovir once the person can tolerate and absorb oral medications, extrapolated from randomized, clinical trial data showing non-inferiority of oral valganciclovir for treatment of CMV disease in people receiving a solid organ transplant (SOT) (AIII).
Oral valganciclovir can be used in patients with mild disease (AIII).
Foscarnet^a 60 mg/kg IV every 8 hours or 90 mg/kg IV every 12 hours (BIII) — for patients with treatment-limiting toxicities to ganciclovir or with ganciclovir resistance; or
Cidofovir^a,b 5 mg/kg/week IV for 2 weeks, then 5 mg/kg IV every other week.
Administer 1 L of normal saline before and, if additional fluid load can be tolerated, administer another 1 L of normal saline after cidofovir infusion.
Administer probenecid 2 g PO 3 hours before each cidofovir dose followed by 1 g PO 2 hours after the dose and 1 g PO 8 hours after the dose (total of 4 g) (CI).
21–42 days or until signs and symptoms have resolved (AIII).

View source ↗

CMV Esophagitis (Not Mild Disease): What to Do When Ganciclovir-Based Therapy Has Not Worked

Clinical Scenario

First-Line Failure Condition

Next-Line Treatment Approach

References